VP of Marketing

Peter Finlayson

Mr. Finlayson is an accomplished commercial leader with nearly 20 years of experience bringing to market therapies that have transformed treatment paradigms for patients with rare and serious diseases.  His expertise spans marketing, market access, commercial strategy, and account management. He has held leadership roles at global biopharmaceutical companies and emerging biotechnology companies.

Mr. Finlayson spent nearly a decade at Genentech, where he contributed to multiple successful specialty product launches. Notably, he led the cross-functional team responsible for the launch of Ocrevus® (ocrelizumab), the first FDA-approved therapy for primary progressive multiple sclerosis (MS). The launch surpassed analyst expectations, and within six months, Ocrevus became the most prescribed MS therapy in the United States.

Most recently, Mr. Finlayson served as Vice President of Marketing at Partner Therapeutics, where he led the commercial launch of Bizengri®, the first FDA-approved therapy for patients with advanced cancers harboring NRG1 gene fusions, a rare genomic alteration. He has also held commercial leadership positions at Vir Biotechnology, Inflection Medicine, and Pardes Biosciences, and supported multiple successful product launches as a consultant at ZS Associates, a global healthcare consulting firm.

Mr. Finlayson is a longtime advocate for rare disease communities. He serves on the Board of Directors of the Hydrocephalus Association and co-founded Team Hydro Foundation, a nonprofit dedicated to raising funds and awareness for hydrocephalus research. He earned both his undergraduate and graduate degrees from Stanford University.